Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer*, Melanie E. Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B. Ottevanger, Jonathan A. Ledermann, Pearly Khaw, Romerai D'Amico, Anthony Fyles, Marie-Helene Baron, Ina M. Jurgenliemk-Schulz, Henry C. Kitchener, Hans W. Nijman, Godfrey Wilson, Susan Brooks, Sergio Gribaudo, Diane Provencher, Chantal HanzenRoy F. Kruitwagen, Vincent T. H. B. M. Smit, Naveena Singh, Viet Do, Andrea Lissoni, Remi A. Nout, Amanda Feeney, Karen W. Verhoeven-Adema, Hein Putter, Carien L. Creutzberg, PORTEC Study Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1273-1285
Number of pages13
JournalLancet oncology
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 2019

Keywords

  • CARCINOMA PATIENTS
  • OPEN-LABEL
  • III TRIAL
  • CHEMOTHERAPY
  • RADIATION
  • MULTICENTER
  • IRRADIATION
  • THERAPY

Cite this

de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., D'Amico, R., Fyles, A., Baron, M-H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Gribaudo, S., Provencher, D., ... PORTEC Study Grp (2019). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet oncology, 20(9), 1273-1285. https://doi.org/10.1016/S1470-2045(19)30395-X